Selvaraj, S., Vidula, M. K., Claggett, B., Rojulpote, C., Bhattaru, A., Clancy, C. B., … Bravo, P. E. (2024). Diagnostic Utility of SGLT2 Inhibitors to Facilitate Myocardial Glucose Suppression During Evaluation of Myocardial Inflammation. JACC Cardiovasc Imaging, 17(7), 827–829. https://doi.org/10.1016/j.jcmg.2024.02.011

Selvaraj, Senthil, Mahesh K. Vidula, Brian Claggett, Chaitanya Rojulpote, Abhijit Bhattaru, Caitlin B. Clancy, Milton Rossman, Daniel A. Pryma, Lee R. Goldberg, and Paco E. Bravo. “Diagnostic Utility of SGLT2 Inhibitors to Facilitate Myocardial Glucose Suppression During Evaluation of Myocardial Inflammation.” JACC Cardiovasc Imaging 17, no. 7 (July 2024): 827–29. https://doi.org/10.1016/j.jcmg.2024.02.011.

Selvaraj S, Vidula MK, Claggett B, Rojulpote C, Bhattaru A, Clancy CB, et al. Diagnostic Utility of SGLT2 Inhibitors to Facilitate Myocardial Glucose Suppression During Evaluation of Myocardial Inflammation. JACC Cardiovasc Imaging. 2024 Jul;17(7):827–9.

Selvaraj, Senthil, et al. “Diagnostic Utility of SGLT2 Inhibitors to Facilitate Myocardial Glucose Suppression During Evaluation of Myocardial Inflammation.” JACC Cardiovasc Imaging, vol. 17, no. 7, July 2024, pp. 827–29. Pubmed, doi:10.1016/j.jcmg.2024.02.011.

Selvaraj S, Vidula MK, Claggett B, Rojulpote C, Bhattaru A, Clancy CB, Rossman M, Pryma DA, Goldberg LR, Bravo PE. Diagnostic Utility of SGLT2 Inhibitors to Facilitate Myocardial Glucose Suppression During Evaluation of Myocardial Inflammation. JACC Cardiovasc Imaging. 2024 Jul;17(7):827–829.